
    
      "Each participant will receive JS016 or matched placebo intravenous infusion on D1
      (randomizing day). Non-pharmaceutical supportive background therapy (e.g. oxygen inhalation)
      for COVID-19 is allowed per clinical needs.

      Investigators will be kept blinded to review the preliminary efficacy and safety data on a
      regular basis. Meanwhile, a study evaluation team (SET) composed of medical monitors, safety
      assessors and statisticians will be set up to review the study status, safety and preliminary
      efficacy of the participants at the pre-specified time points or as necessary.
    
  